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Objective: The aim of this study is to investigate the effects of exercise as an add-on 
therapy with antidepressant medication and cognitive behavioral group therapy (CBGT) 
on treatment outcomes in low-active major depressive disorder (MDD) patients. We 
also explored whether exercise reduces the residual symptoms of depression, notably 
cognitive impairment and poor sleep quality, and aimed to identify putative biochemical 
markers related to treatment response.
Methods: Sixteen low-active MDD patients were recruited from a mental health day 
treatment program at a local hospital. Eight medicated patients performed an 8-week 
exercise intervention in addition to CBGT, and eight medicated patients attended the 
CBGT only. Twenty-two low-active, healthy participants with no history of mental health 
illness were also recruited to provide normal healthy values for comparison.
results: Results showed that exercise resulted in greater reduction in depression 
symptoms (p = 0.007, d = 2.06), with 75% of the patients showing either a therapeutic 
response or a complete remission of symptoms vs. 25% of those who did not exercise. In 
addition, exercise was associated with greater improvements in sleep quality (p = 0.046, 
d = 1.28) and cognitive function (p = 0.046, d = 1.08). The exercise group also had 
a significant increase in plasma brain-derived neurotrophic factor (BDNF), p = 0.003, 
d =  6.46, that was associated with improvements in depression scores (p =  0.002, 
R2 = 0.50) and sleep quality (p = 0.011, R2 = 0.38).
conclusion: We provide evidence that exercise as an add-on to conventional anti-
depressant therapies improved the efficacy of standard treatment interventions. Our 
results suggest that plasma BDNF levels and sleep quality appear to be good indicators 
of treatment response and potential biomarkers associated with the clinical recovery 
of MDD.
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inTrODUcTiOn
Major depressive disorder (MDD) is a global public health prob-
lem being the second leading cause of disability worldwide (1, 2) 
and projected to be the leading cause by 2030 (2). Epidemiological 
research suggests that 3.8% of Canadians report a depressive epi-
sode within the past year (3), and the lifetime prevalence is 12.6% 
(4). It has been estimated that merely half of depressed individuals 
seek medical treatment, and among those who do seek help, just 
over 30% receive an efficacious treatment (5–9). Furthermore, 
over 40% of MDD patients who are considered in partial or full 
remission continue to experience residual symptoms and are at 
greater risk for relapse, highlighting the need for more efficacious 
antidepressant therapies (10, 11).
Major depressive disorder is a clinically and biologically het-
erogeneous disorder that frequently coexists with other medical 
illnesses (12). Consequently, the etiology and pathogenesis of 
MDD is thought to be multifaceted, making it very challenging for 
researchers to develop novel efficacious antidepressant therapies. 
Converging evidence from brain imaging and neuropathological 
studies in humans and animals have linked MDD to structural, 
functional, and cellular changes within the hippocampal forma-
tion. People with MDD have consistently been found to have 
reduced hippocampal volumes (13–15) and impaired hippocam-
pal function during memory encoding and retrieval processes 
(16–20).
Growing evidence has suggested that reductions in neuro-
trophins and growth factors, particularly brain-derived neuro-
trophic factor (BDNF), to be a central player for both the onset 
of MDD and recovery once levels are normalized (21–26). BDNF 
is an activity-dependent secreted protein that plays a critical role 
in synaptic plasticity processes underlying learning and memory 
(27). Therapeutic interventions that augment neuroplasticity, via 
increases in BDNF, have been shown to reverse the pathologi-
cal effects of depression (28–30). A growing body of research is 
also suggesting that a chronic inflammatory response may also 
play a role in the pathogenesis of MDD (31, 32). The inflam-
matory hypothesis of depression was founded on the common 
comorbidity of depression-like behaviors with systemic infection, 
cancer, and autoimmune diseases (33). Increased levels of pro-
inflammatory interleukin (IL)-1β, IL-6, and tumor necrosis factor 
(TNF)-α and decreased levels of anti-inflammatory IL-1 receptor 
antagonist and IL-10 are the most commonly reported cytokines 
in the depression literature (34–40). More recently, Moon et al. 
(41) identified the cysteine proteinases CTSB (CTHB) to be a 
novel protein that may play a key role in the beneficial effects of 
exercise on neural function.
Several studies have reported that exercise alone or in combi-
nation with other therapies to be as efficacious in treating mild 
to moderate depression with response rates similar to antide-
pressant medication and cognitive behavioral therapy (42–47). 
Furthermore, it has been shown to improve cognitive function 
(48) and sleep quality (49), which are the two of the most fre-
quently reported residual symptoms among patients with MDD 
who achieve remission (50). Exercise for depression has also 
been shown to increase hippocampal volume (51) and increase 
serum BDNF concentrations (52) and may be a neuroprotective 
mechanism that maintains cognitive ability in older age (53). 
The beneficial effects of exercise on overall brain health have also 
been observed in other populations. In elderly adults, exercise 
protects against the development of neurodegenerative diseases 
(54), reverses age-associated brain volume loss (55, 56), improves 
memory performance (57, 58), and improves executive function 
(59). Exercise has also been shown to facilitate neurocognitive 
recovery from traumatic brain injury (60, 61) and increase hip-
pocampal volume in schizophrenics (62).
The main objective of this exploratory feasibility study is to 
explore the effects of combining exercise as an add-on therapy 
with antidepressant medication and cognitive behavioral group 
therapy (CBGT) treatment outcomes in low-active individuals. 
Sedentary time has been shown to be positively associated with 
low-grade chronic inflammation in non-depressed populations 
(63), while BDNF levels are higher in cardiorespiratory fit 
individuals vs. unfit individuals (64). As such, the research inves-
tigating the underlying mechanism involved in the etiology and 
pathogenesis of MDD may be confounded by low physical activity 
levels and sedentary behavior time that tend to be more prevalent 
in depressed populations (53). For this reason, we specifically 
recruited low-active MDD patients and controls to control for 
variations in baseline fitness level. In addition to reduction in 
depressive symptoms, we were interested in exploring if exercise 
reduces the residual symptoms of depression, notably cognition 
and sleep quality, and identifying putative biochemical biomark-
ers (such as BDNF, cytokines, and CTHB) related to treatment 
response. These findings provide preliminary evidence, which 
can be used to focus future research aimed at understanding of 
the etiology and pathophysiology of MDD as well as indicators 
associated with treatment response in exercise.
MaTerials anD MeThODs
All procedures were approved by the University and Hospital 
Institutional Review Boards, and all participants provided written 
informed consent. The study was registered with Clinicaltrials.
gov (#NCT03191994).
Participants
Sixteen low-active patients (mean age = 39.31 years, SD = 7.02; 
12 females) with comorbid MDD and anxiety were recruited 
from an outpatient CBGT program at a local hospital in Oshawa, 
Ontario, Canada. Twenty-two low-active, healthy participants 
(mean age =  20.63, SD =  1.19; 11 females) with no history of 
mental health illness or neurological disease were also recruited 
from a local university in Oshawa, Ontario Canada to provide 
normal healthy values for comparison. Depressed participants 
(n =  16) had a confirmed diagnosis of MDD according to an 
unstructured clinical interview by hospital psychiatrists based on 
the criteria from the Diagnostic and Statistical Manual of Mental 
Disorders—Fourth Edition [DSM-IV-TR (65)] and a score of ≥20 
on the Beck Depression Inventory—Second Edition [BDI-II: A 
(66)]. Eligible MDD participants had no co-existing DSM-IV-TR 
Axis I disorders apart from anxiety. MDD participants were eligi-
ble if their pharmacological medication was stabilized a minimum 
of 6  weeks prior to study enrollment, experienced depression 
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symptoms for a minimum of 6 months, and screened negative 
on the Global Appraisal of Individual Needs for substance abuse 
(67). MDD and healthy participants were considered low active 
if they exercise for less than 20 min, three times per week. All 
participants were screened with the Physical Activity Readiness 
Questionnaire to ensure they had no medical contraindications 
to physical activity.
Psychometric Measures: anxiety, 
Depression, sleep Quality
The BDI-II (66, 68) was used to measure depression severity. 
The BDI-II is the most commonly used self-reported instrument 
that measures depression severity ranging from mild to severe. 
The BDI-II has excellent internal consistency, with a coefficient 
alpha of 0.91 (68). Depression was measured using the BDI-II 
(66), which is one of the most widely used self-reported instru-
ment capable of measuring depression severity ranging from not 
depressed to severely depressed (68). The Hospital Anxiety and 
Depression Scale (HADS) was used to measure both depression 
and anxiety (69). The HADS is also a reliable and widely used 
self-reporting instrument that consists of two 7-item subscales, 
one measuring anxiety (HADS-A) and one measuring depres-
sion (HADS-D) that assesses feelings of anxiety and depression. 
The HADS-A and HADS-D have good internal consistency, with 
coefficient alphas of 0.83 and 0.82, respectively (70). Poor sleep 
quality is one of the two most frequently reported residual symp-
tom among patients with MDD who achieve remission (50). The 
Pittsburgh Sleep Quality Index (PSQI) was used to measure sleep 
quality during the previous month (71). The PSQI is a 19-item 
questionnaire that measures 7 components of sleep quality 
including subjective sleep quality, sleep latency, sleep duration, 
habitual sleep efficiency, sleep disturbances, use of sleeping medi-
cations, and daytime dysfunction. The maximum PSQI score is 
21 points, and an overall PSQI score of >5 points indicates that 
the individual has poor sleep quality. The PSQI has good internal 
consistency, with a coefficient alpha of 0.83 (71).
cognitive Measures
Cognitive impairment is one of the two most frequently reported 
residual symptoms among patients with MDD who achieve 
remission (50). To assess cognitive performance within selected 
domains, we used a computerized cognitive battery, the Cambridge 
Neuropsychological Test Automated Battery (CANTAB; Cambridge 
Cognition, Cambridge, UK; http://www.cambridgecognition.
com/cantab/cognitive-tests/). The CANTAB is a fast and accurate 
method to assess cognitive functioning (72) and shown to possess 
acceptable to high levels of concurrent validity and test–retest 
reliability (73). Each test is presented on a computer touch screen 
and uses non-verbalizable patterns presented in a game-like 
format that provides immediate feedback to maintain interest 
and reduce boredom (74). Three CANTAB tests were included in 
our assessment battery that have been previously used to identify 
impaired cognitive function in MDD and shown to be sensitive to 
changes in the hippocampus and frontal lobes (75–77). The Paired 
Associates Learning (PAL) assesses visual learning and memory. 
The delayed matching to sample (DMS) assesses recognition 
memory for patterns. The intradimensional/extradimensional set 
shift (IED) is a measure of rule acquisition and reversal, often 
considered a test of cognitive flexibility. In addition, the Montreal 
Cognitive Assessment (MoCA), a brief neurocognitive tool with 
high sensitivity for screening patients with mild cognitive impair-
ment, was used to assess global function. The maximum MoCA 
score is 30 and an overall score ≤25 is indicative of mild cognitive 
dysfunction (78). The MoCA has good internal consistency, with 
a coefficient alpha of 0.83 (78).
Plasma collection
Non-fasted venous blood was collected mid-day from each par-
ticipant prior to the first exercise session and again at 8 weeks by 
venipuncture into ethylenediaminetetraacetic acid tubes. Blood 
samples were prepared within 30 min by centrifugation, and the 
fibrinogen containing plasma supernatant was stored at −85°C 
until assayed. Plasma proteins IL-1β, IL-1Ra, IL-6, IL-10 TNF-α, 
BDNF, and total CTHB were quantified using enzyme-linked 
immunosorbant assays (ELISAs) following manufacturer’s pro-
tocols (R&D Systems, MN, USA; BioLegend, CA, USA). ELISA 
plates were read at a wavelength of 450 nm using a Synergy HTTR 
microplate reader (Bio-Tek Instrumentation, VT, USA).
Fitness assessment
The YMCA cycle ergometer test recommended by the American 
College of Sports Medicine was used to measure cardiorespiratory 
fitness at baseline and 8 weeks (79–81). The YMCA protocol is an 
indirect submaximal exercise test that uses heart rate (HR) meas-
urements to estimate maximal oxygen consumption (VO2max). 
The test consists of two or more consecutive 3-min stages at a 
given workload. The objective is to elevate the participant’s HR 
between 110  bpm and 85% of age-predicted maximal HR for 
two consecutive stages. The first stage of the test was a 25  W 
workload at 50 revolutions per minute. Radial pulse was used to 
measure HR during the final 15 s of each minute to determine 
the workload of the following stages. After a steady-state HR 
(two successive measures that differ, <5 bpm) was within 10 bpm 
of the 85% age-predicted maximum HR, the test was complete. 
VO2max was predicted using the YMCA formula that includes 
workload, body mass, and predetermined constants.
exercise intervention
The 8-week exercise prescription was based on the international 
recommendation to perform a minimum of 150 min per week 
of moderate to vigorous intensity aerobic exercise in addition 
to resistance activities two times per week, for developing and 
maintaining cardiorespiratory, musculoskeletal, and neuromotor 
fitness in healthy adults (82, 83). This minimum recommended 
dose of exercise was prescribed to increase participant adoption 
and adherence since low-active people with depression gener-
ally lack motivation to begin an exercise program (84). Also, 
exercise prescriptions based on this intensity performed over 
6  weeks have shown to significantly improve cardiorespiratory 
fitness and depression symptoms in patients with MDD (85, 86). 
The research has also found that a combining aerobic with resist-
ance training is more effective than aerobic exercise alone in 
improving depressive symptoms and cognitive function (87, 88). 
The CBGT +  exercise (exercise) group performed one aerobic 
TaBle 1 | Baseline characteristics of depressed patients and healthy controls.
Variables MDD (n = 16) healthy (n = 22) p
Demographic
Sex (male/female) 4/12 11/11 0.452
Age (years) 39.31 (7.02) 20.95 (1.25) <0.0001
Psychometric
BDI (depression) 37.50 (8.18) 7.55 (6.15) <0.0001
HADS-Anxiety 15.13 (2.73) 4.77 (3.24) <0.0001
PSQI (sleep) 13.81 (3.47) 4.36 (2.40) <0.0001
Biological
Body mass index (kg/m2) 28.79 (5.17) 24.89 (5.17) 0.045
VO2max (ml/kg/min) 23.40 (6.05)a 21.79 (7.77) 0.510
BDNF (pg/ml) 8,237 (2,163) 8,935 (2,837) 0.415
CTHB (pg/ml) 29,253 (9066) 37,551 (14,867) 0.348
cognitive
MoCA 24.56 (1.67) 26.18 (2.40) 0.026
DMS% correct 85.78 (13.06)a 90.30 (10.02)a 0.241
DMS latency (ms) 4817 (1770)a 3640 (1176)a 0.020
PAL (errors) 24.27 (19.33)a 7.50 (5.03)a 0.0004
IED (errors) 19.07 (12.41)a 22.80 (17.93)a 0.495
BDI, Beck Depression Inventory; BDNF, brain-derived neurotrophic factor; CTHB, 
CTSB; DMS, delayed matching to sample; HADS, Hospital Anxiety and Depression 
Scale; IED, intradimensional/extradimensional shift; MDD, major depressive disorder; 
MoCA, Montreal Cognitive Assessment; PAL, paired associates learning; PSQI, 
Pittsburgh Sleep Quality Index; VO2max, maximum oxygen.
Data are expressed as mean (SD).
aOne missing value.
p-Values < 0.05 were considered statistically significant and are represented in bold.
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only and two resistance (with a shorter bout of aerobic activity) 
weekly sessions for a duration of 8 weeks. All exercise sessions 
were performed alone, on non-consecutive days and each session 
were supervised by a qualified exercise professional to increase 
participant compliance and to ensure all participants fulfilled the 
exercise prescription (89). The exercise intensity for aerobic and 
resistance sessions was based on a target HR between 60 and 80% 
of their age-predicted maximum HR. The aerobic workloads were 
determined by HR response and increased by 5-min increments 
over the course of the 8 weeks, reaching a maximum of 60 min 
per session. Resistance sessions incorporated a whole-body exer-
cise prescription using the larger muscle groups, and workloads 
were approximately 95% of the 10 repetition maximum to ensure 
proper form. Resistance exercises were performed in two or 
three supersets (one set of each exercise with no rest between 
sets) with an 8–12 repetition range to decrease rest times and 
to maintain target HR. Radial pulse was measured throughout 
each exercise session to ensure that participants maintained their 
target HR. Attendance was recorded, and only those participants 
who completed >80% of the exercise sessions were included in 
the analysis. For a full description of the exercise intervention, 
please see Ref. (90).
statistical analysis
All statistical analyses were conducted using GraphPad Prism, 
v6 (La Jolla, CA, USA). Continuous data are presented as means 
(SDs). Categorical data are presented as frequencies. Baseline 
group differences were compared using a two-tailed Student’s 
t-test and Fisher’s exact test. Paired t-tests were used to compare 
the pre–post change for each group, and a two-way repeated 
measures analysis of variance (ANOVA) was used to determine 
group-by-time interactions. p less than 0.05 were considered 
statistically significant. Effects sizes were determined using a 
modified version of Cohen’s D (dppc2) method, which divides the 
difference in mean pre–post change between groups by the base-
line pooled SD to account for any baseline differences (91). FDR 
correction was performed on all p values for t-tests and ANOVAs 
assessing the effects of exercise to confirm that they survived cor-
rection for multiple comparisons. The criteria used to determine 
remission and response rates were BDI cut-off scores ≤11 and 
≥47%, respectively (92). Simple linear regression analyses were 
performed to examine the relationship between pre–post changes 
in plasma BDNF levels and BDI scores, sleep quality, and correct 
response latency.
resUlTs
Baseline characteristics between MDD 
and healthy groups
Analysis revealed no significant difference in gender distribution 
between groups (p = 0.182). As expected, the MDD group was sig-
nificantly older than the healthy group, t(36) = 12.31, p < 0.0001, 
given that we intentionally recruited younger individuals to 
provide normative data for comparison from healthy individuals 
with no history of mental health illness or other confounding 
pathologies that increase with age. Results showed that patients 
with MDD had a significantly elevated BDI score, t(36) = 12.90, 
p  <  0.0001; HADS-A score, t(36)  =  13.07, p  <  0.0001; and 
PSQI score, t(36) =  9.94, p <  0.0001, compared to the healthy 
controls. The MDD group had a significantly greater body mass 
index compared to the healthy group, t(36) = 2.08, p = 0.045. A 
single participant from the exercise group discontinued baseline 
VO2max testing due to exhaustion and was excluded from the 
VO2max analysis. There were no significant differences between 
the groups for VO2max, BDNF, and CTHB. Cytokine data for 
IL-1β, IL-1ra, IL-6, and TNF-α were not included in the para-
metric analysis since greater than 50% of the values were below 
the level of detection. Therefore, we compared the frequencies 
of detectable cytokine concentrations between the groups using 
Fisher’s exact test. Results showed no differences between groups 
in frequency of individuals with detectable circulating concentra-
tions of IL-1β, IL-1ra, IL-6, IL-10, and TNF-α (p > 0.05), sug-
gesting that depressed subjects were not displaying classical signs 
of systemic inflammation at the study baseline. Cognitive tests 
revealed that the MDD group performed significantly poorer on 
the MoCA, t(36) = 2.32, p = 0.026; had significantly more errors 
for the PAL test, t(35) = 3.90, p = 0.0004; and had a significantly 
longer correct response latency for the DMS test t(35) =  2.44, 
p =  0.020, suggesting cognitive impairment. Performance did 
not differ between groups for the DMS and IED cognitive tests 
(p > 0.05). See Table 1.
Baseline characteristics between MDD 
groups
At baseline, the exercise group had a significantly higher BDI score 
compared to the CBGT only (non-exercise) group, t(14) = 2.38, 





Sex (male/female) 1/7 3/5 0.248
Age (years) 37.25 (8.00) 41.38 (5.66) 0.253
Education (years) 13.25 (2.19) 13.50 (1.41) 0.790
Cumulative illness duration 
(years)
3.57 (3.21) 3.00 (3.02) 0.432
Psychometric
BDI (depression score) 41.75 (3.50) 33.25 (9.48) 0.032
HADS-Anxiety 15.63 (1.77) 14.63 (3.50) 0.483
PSQI (sleep score) 14.38 (3.46) 13.25 (3.62) 0.535
Biological
Body mass index (kg/m2) 28.33 (5.12) 29.25 (5.52) 0.734
VO2max (ml/kg/min) 24.82 (8.00)a 22.16 (3.80) 0.416
BDNF (pg/ml) 7,108.48 (596.51) 9,363.74 (730.75) 0.031
CTHB (pg/ml) 37,580 (10,284) 48,102 (25,327) 0.295
cognitive
MoCA 24.63 (1.41) 24.50 (2.00) 0.887
DMS% correct 90.48 (6.50)a 81.67 (16.23)a 0.203
DMS latency (ms) 4,857 (1,648)a 4,781 (1,983)a 0.938
PAL (errors) 22.14 (20.93)a 26.13 (19.05)a 0.706
IED (errors) 20.57 (16.09)a 17.75 (9.04)a 0.677
BDI, Beck Depression Inventory; BDNF, brain-derived neurotrophic factor; BMI, 
body mass index; CBGT, cognitive behavioral group therapy; CTHB, CTSB; DMS, 
delayed matching to sample; HADS, Hospital Anxiety and Depression Scale; IED, 
intradimensional/extradimensional shift; MoCA, Montreal Cognitive Assessment; PAL, 
paired associates learning; PSQI, Pittsburgh Sleep Quality Index; VO2max, maximum 
oxygen consumption.
Data are expressed as mean (SD).
aOne missing value.
p-Values < 0.05 were considered statistically significant and are represented in bold.
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p = 0.032, indicating greater depression severity. The non-exercise 
group had significantly higher plasma BDNF concentrations 
compared to the exercise group, t(14) = 2.40, p = 0.031. There 
were no other baseline differences between groups (see Table 2). 
More than 50% of the patients did not have detectable plasma 
cytokine concentrations and were not included in the parametric 
analysis. Therefore, we conducted a Fisher’s exact text on the 
frequencies of detectable plasma cytokine concentrations and 
found no group differences at baseline (p > 0.05).
Pre–post Measures for MDD groups
Depressive Symptoms
Both MDD groups showed a statistically significant decrease 
in BDI and HADS-D scores following treatment. A two-way 
repeated measures ANOVA revealed a group-by-time interac-
tion, f(1,14) = 10.18, p = 0.007, and a large effect size of d = 2.06, 
indicating that the exercise group had a greater reduction in 
BDI scores compared to the non-exercise group at 8 weeks (see 
Figure  1A; 63 vs. 27%). Moreover, 75% of the patients in the 
exercise group showed either a therapeutic response or complete 
remission of symptoms vs. 25% of the non-exercise group (see 
Figure 2).
Sleep Quality
The exercise group showed a significant decrease in PSQI scores 
(p = 0.010), while the non-exercise group showed no significant 
change (p =  0.09). There was also a significant group-by-time 
interaction, f(1,14) = 4.81, p = 0.046, and an effect size of d = 1.28, 
suggesting that exercise was effective in improving sleep quality 
(see Figure 1B).
Biological Markers
There was no group-by-time interaction for VO2max pre–post. 
However, the exercise group showed a 31% increase in VO2max 
that was marginally significant t(6) = 2.17, p = 0.073, suggest-
ing that the exercise intervention was successful at improving 
cardiorespiratory fitness (see Table  3). Biochemical marker 
analyses revealed a significant increase in plasma BDNF levels 
for the exercise group at 8 weeks with a group-by-time interaction 
[f(1,14) =  12.47, p =  0.003] and a large effect size of d =  6.46 
(see Figure 1C). There were no pre–post changes in CTHB or 
cytokines in either group. A simple linear regression revealed that 
changes in BDNF were significantly associated with changes in 
BDI and PSQI scores, indicating that those who experienced a 
greater increase in BDNF also experienced greater improvement 
in depression and sleep quality (see Figure  3). No significant 
relationship for changes in BDNF and correct response latency 
was found (p = 0.190).
Cognition
There were no changes in performance for the MoCA, DMS, PAL, 
or IED tasks for either group at 8  weeks. A two-way repeated 
measures ANOVA revealed a group-by-time interaction for the 
DMS correct response latency [f (1,13) = 4.85, p = 0.046] and a 
large effect size of d = 1.08, indicating that the exercise group was 
significantly faster in making a correct decision postintervention 
(see Table 3).
DiscUssiOn
This feasibility study investigated the effects of an 8-week exercise 
prescription, based on the minimal recommended dose and on 
a series of symptom, biochemical, and cognitive measures. Our 
preliminary study provides evidence that exercise as an add-on 
therapy led to higher remission/treatment response rates vs. more 
common treatment approaches alone. In addition, we found 
that exercise improves sleep quality and cognitive function, and 
BDNF levels increased in the exercise group posttreatment. These 
changes in BDNF were significantly associated with symptom 
improvement in depression and sleep quality scores, providing 
potential biomarkers of treatment response. We also did not 
observe any significant differences between MDD patients and 
healthy controls for plasma CTHB, anti-inflammatory and pro-
inflammatory cytokines, and no changes pre–post, suggesting 
BDNF may be a specific marker for the positive changes, which 
come about following an exercise intervention in patients who do 
not have comorbid inflammation.
Our results provide evidence for the therapeutic use of 
exercise in treating MDD collaborating with previous findings 
that exercise as an add-on therapy to ADM is more efficacious in 
alleviating MDD symptoms than ADM alone (93, 94). While the 
sample in our study was small, the added benefit of an exercise 
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FigUre 1 | Individual group plots illustrating pre–post changes for (a) BDI depression scores, (B) PSQI scores, and (c) BDNF levels. BDI, Beck Depression 
Inventory; BDNF, brain-derived neurotropic factor; CBGT, cognitive behavioral group therapy; PSQI, Pittsburgh Sleep Quality Index.
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FigUre 2 | Responders, non-responders, and remissive MDD patients at 
8 weeks for each group. Treatment response and remission rates were 
greater for the exercise group (N = 6) compared to (N = 2) for the non-
exercise group. Responders represent patients with a greater than or equal 
to a 47% reduction BDI score at 8 weeks compared to baseline, and 
remission represents patients with a BDI score less than or equal to 11. BDI, 
Beck Depression Inventory; CBGT, cognitive behavioral group therapy; MDD, 
major depressive disorder.
TaBle 3 | Pre–post changes for depressed groups.
Measure cBgT + exercise (n = 8) cBgT (n = 8) Between-group analysis
Pre, mean (sD) Post, Mean (sD) p d Pre, mean (sD) Post, mean (sD) p d F p dppc2
Psychometric
BDI 41.75 (3.50) 15.50 (10.43) 0.0004* 2.89 33.25 (9.48) 24.38 (10.01) 0.042 0.91 10.80 0.007* 2.38
HADS-Depression 13.63 (2.97) 5.88 (2.23) <0.0001* 2.86 12.00 (3.59) 9.75 (3.73) 0.034 0.61 20.91 0.0004* 1.63
HADS-Anxiety 15.63 (1.77) 11.38 (4.53) 0.010* 0.90 14.63 (3.50) 11.25 (2.38) 0.030 1.11 0.253 0.623 0.31
PSQI (sleep) 14.38 (3.46) 7.75 (4.20) 0.011* 1.68 13.25 (3.62) 11.38 (3.30) 0.090 0.54 4.81 0.046 1.32
Biological
BMI (kg/m2) 28.33 (5.12) 28.29 (4.48) 0.934 0.01 29.25 (5.52) 29.95 (5.36) 0.068 0.13 1.84 0.196 0.14
VO2max (ml/kg/min) 24.82 (8.00) a 32.52 (10.12)a 0.073 0.83 22.16 (3.80) 26.42 (8.17) 0.130 0.60 0.659 0.432 0.54
BDNF (pg/ml) 7,107 (596.51) 10,642 (957.45) 0.008* 1.54 9,363 (730.75) 8,497 (943.75) 0.304 0.36 12.47 0.003* 6.46
CTHB (pg/ml) 37,580 (10,284) 39,293 (14,278) 0.697 0.13 48,102 (25,327) 55,477 (22,450) 0.109 0.30 0.947 0.347 0.28
cognitive
MoCA 24.63 (1.41) 25.75 (2.38) 0.229 0.56 24.50 (2.00) 25.75 (2.71) 0.380 0.40 0.006 0.938 0.07
DMS% correct 90.48 (6.50)a 89.48 (3.50)a 0.721 0.19 81.67 (16.23) 80.00 (21.97) 0.844 0.09 0.005 0.943 0.05
DMS latency (ms) 4,857 (1,648)a 2,650 (510.50)a 0.010* 1.68 4,781 (1,983) 4,601 (3785) 0.800 0.02 4.85 0.046 1.08
PAL (errors) 22.14 (20.93)a 19.86 (11.44)a 0.772 0.13 25.13 (19.05) 19.63 (21.14) 0.056 0.33 0.304 0.591 0.16
IED (errors) 20.57 (16.09)a 18.57 (7.59)a 0.774 0.16 17.75 (9.04) 19.50 (7.62) 0.666 0.21 0.252 0.624 0.28
*p < 0.05 FDR corrected across the whole table.
BMI, body mass index; BDI, Beck Depression Inventory; BDNF, brain-derived neurotropic factor; CBGT, cognitive behavioral group therapy; d, Cohen’s D; dppc2, Cohen’s D; DMS, 
delayed matching to sample; HADS, Hospital Anxiety and Depression Scale; IED, intradimensional/extradimensional shift; MoCA, Montreal Cognitive Assessment; PAL, Paired 
Associates Learning; PSQI, Pittsburgh Sleep Quality Index; VO2max, maximum oxygen consumption.
Data are expressed as mean (SD).
aOne missing value.
p-Values < 0.05 were considered statistically significant and are represented in bold.
7
Gourgouvelis et al. Benefits of Exercise for MDD
Frontiers in Psychiatry | www.frontiersin.org March 2018 | Volume 9 | Article 37
be partly mediated by increases in neurotrophic growth factors 
that promote neuroplasticity, particularly BDNF. Consistent 
with the exercise-induced increase in BDNF observed in our 
sample, the rodent literature has shown exercise to increase hip-
pocampal BDNF (95, 96); enhance adult neurogenesis (97, 98), 
synaptogenesis (99), and angiogenesis (100); improve dendritic 
morphology (101, 102); and enhance learning and memory (103). 
However, in humans, the link between exercise and BDNF is less 
clear. Acute exercise has consistently been shown to increase 
peripheral BDNF levels in healthy (104–106), those with MDD 
(107, 108), and elderly (109) individuals, whereas the long-term 
effects of exercise on resting BDNF concentrations have been 
mixed (64, 110). Exercise has also been shown to reduce systemic 
inflammation in other pathological conditions such as cardio-
vascular disease and type 2 diabetes mellitus (111–113). Studies 
have reported a simultaneous increase in the systemic levels of 
cytokines with anti-inflammatory properties including IL-10 and 
IL-1ra and a decrease in the pro-inflammatory cytokines IL-6 and 
TNF-α (114, 115).
The increase in plasma BDNF concentration and the associ-
ated decrease in depressive symptoms and improvements in sleep 
quality observed in the exercise group adds further support to 
the interplay between depression, sleep quality, and BDNF that 
may underlie the onset and recovery of MDD (116). Sleep distur-
bances are reported by up to 90% of depressed subjects (117, 118), 
and sleep studies have shown that depression is associated with 
reductions in slow-wave activity (SWA), a reliable EEG marker 
of sleep homeostasis (119, 120). SWA is an essential mechanism 
for restoring synaptic plasticity processes associated with learn-
ing and memory (121, 122). BDNF is necessary for the birth, 
survival, and function of neurons in the adult brain (123–126). 
Furthermore, BDNF is a mediator of activity-dependent synaptic 
intervention had a large effect size with respect to the changes in 
clinical scores. The efficacy of exercise is further substantiated by 
the fact that 75% of the patients in the exercise group achieving 
either remission or a therapeutic response vs. only 25% in the 
non-exercise group. This represents substantive improvement 
in outcomes with the addition of a relatively low-cost add-on 
intervention.
To the best of our knowledge, this is the first study to investi-
gate the effects of exercise in combination with ADM and CBGT 
specifically in a low-active MDD population. As such, there are 
limited data to compare our research findings. The molecular link 
between exercise and depression is not well understood but may 
A B
FigUre 3 | (a) Linear regression of pre–post changes for BDI and PSQI scores against BDNF change, irrespective of group. (a) A significant negative correlation 
was found for (a) BDI scores and BDNF levels (p = 0.002, R2 = 0.50) and (B) PSQI scores and BDNF levels (p = 0.011, R2 = 0.38), indicating that improvements in 
depression and sleep quality scores are associated with an increase in BDNF levels. BDI, Beck Depression Inventory; BDNF, brain-derived neurotropic factor; PSQI, 
Pittsburgh Sleep Quality Index.
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plasticity and has been suggested to be the molecular mechanism 
that links synaptic plasticity and the homeostatic sleep response 
(127, 128). Rats administered higher levels of intracortical injec-
tions of BDNF during wakefulness show a stronger SWA response 
during subsequent sleep and stronger synaptic potentiation dur-
ing waking. However, this effect is reversed when blocking BDNF 
during wakefulness (129). As such, one possible mechanisms of 
the improved sleep quality of patients in the exercise group may 
be the increase in plasma BDNF concentrations brought about 
via increased physical activity.
Our initial baseline comparison between MDD patients and 
healthy controls revealed that the MDD patients performed below 
the healthy controls on the hippocampal-dependent cognitive 
tests. These behavioral results complement our previous fMRI 
findings that explored the effects of an 8-week exercise interven-
tion on hippocampal function during a memory encoding task, 
in low-active/low-fit MDD and healthy individuals (90). Despite 
no pre–post change in memory performance for either group, 
there was a consistent deactivation pattern in the hippocampus 
and other memory-related brain regions during the memory 
encoding process. This deactivation pattern was common among 
both the MDD and healthy groups, suggesting that exercise may 
have a generalized effect on brain function in low-active/low-fit 
individuals by enhancing neural network processing efficiency 
while still resulting in a greater mood effect for those suffering 
from MDD. Electroencephalographic studies have also found 
that active individuals showed less PFC activation and signifi-
cantly faster reaction times compared to low-active individuals, 
indicating that physically active individuals require less cognitive 
resources and effortful task preparation that results in faster 
information processing speeds (130).
limitations
The sample size of this feasibility study is small; thus, even 
though the exercise group experienced a concomitant decrease 
in depression severity and increase in plasma BDNF, our results 
must be considered preliminary. Another possible limitation is 
that our MDD samples were undergoing ADM, which may have 
affected our baseline comparison with healthy controls. However, 
to maximize the external validity of our results, we included 
medicated patients to replicate the typical patient seen in “real-
world” clinical practice, to maximize the external validity of our 
results, including patients already on ADM, actually increases the 
external validity. Furthermore, since our sample was composed of 
low-active MDD patients, we cannot be certain if the link between 
BDNF, depression, and sleep quality exists in high-fit/high-active 
MDD patients. There is a lack of reporting physical activity 
levels and cardiorespiratory fitness parameters in the MDD 
literature. Therefore, significant differences observed in studies 
that compare MDD to healthy individuals may be confounded by 
a sedentary lifestyle that may be more common in MDD. Future 
studies must compare “fit” vs. “low-fit” MDD groups to identify 
biological markers, independent of cardiorespiratory fitness and 
specific to MDD.
Practical implications
This study adds to a growing body of literature suggesting the 
beneficial effects of exercise as an adjunct therapy for the treat-
ment of depression. The effects of exercise may be twofold: first to 
reduce depressive symptoms and second to improve overall sleep 
quality. Our study adds to the existing literature by including a 
well-defined exercise prescription based on the validated metrics 
and titrated to an individual’s fitness level. This combined aerobic 
and resistance exercise prescription, based on the minimum rec-
ommended dose, was well tolerated and adhered to throughout 
the 8  weeks by low-active MDD patients, giving health care 
practitioners potential guidelines for prescribing exercise to their 
patients. Such interventions can be added to clinical practice 
with minimal additional equipment or expertise and if needed 
could be approximated by having patients join existing exercise 
programs and classes, which may be available at private institu-
tions such as a local gym.
cOnclUsiOn
The design of this feasibility study allowed for a “real-world” 
therapeutic approach that addresses effectiveness while also 
measuring biochemical markers shown to be altered in MDD. 
We provide preliminary evidence that exercise as an add-on to 
conventional antidepressant therapies may be more efficacious 
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in treating MDD than no exercise. We also found that improve-
ments in depression and sleep quality were associated with an 
increase in plasma BDNF concentration following exercise, 
providing a potential biological marker for treatment outcome. 
While the role of BDNF as a biomarker for depression and treat-
ment outcome may be controversial (110), these results suggest 
the potential clinical importance of measuring peripheral BDNF 
concentrations and sleep quality in MDD patients to monitor 
changes over the course of treatment that may elucidate markers 
of clinical recovery.
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